187 related articles for article (PubMed ID: 12447149)
21. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of prospective randomized controlled trials comparing intracoronary versus intravenous abciximab in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shimada YJ; Nakra NC; Fox JT; Kanei Y
Am J Cardiol; 2012 Mar; 109(5):624-8. PubMed ID: 22152971
[TBL] [Abstract][Full Text] [Related]
23. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
[TBL] [Abstract][Full Text] [Related]
24. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
[TBL] [Abstract][Full Text] [Related]
25. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.
Coto H
J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214
[TBL] [Abstract][Full Text] [Related]
26. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
[TBL] [Abstract][Full Text] [Related]
27. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
[TBL] [Abstract][Full Text] [Related]
28. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
[TBL] [Abstract][Full Text] [Related]
29. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy.
Reddy MS; Carmody TJ; Kereiakes DJ
Catheter Cardiovasc Interv; 2001 Apr; 52(4):486-8. PubMed ID: 11285605
[TBL] [Abstract][Full Text] [Related]
30. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
Elmi F; Oza R; Mascarenhas DA
J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
[TBL] [Abstract][Full Text] [Related]
31. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
[TBL] [Abstract][Full Text] [Related]
32. Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists.
Stiegler HM; Fischer Y; Steiner S
Lancet; 1999 Apr; 353(9159):1185. PubMed ID: 10210005
[No Abstract] [Full Text] [Related]
33. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry.
Dudek D; Siudak Z; Janzon M; Birkemeyer R; Aldama-Lopez G; Lettieri C; Janus B; Wisniewski A; Berti S; Olivari Z; Rakowski T; Partyka L; Goedicke J; Zmudka K;
Am Heart J; 2008 Dec; 156(6):1147-54. PubMed ID: 19033011
[TBL] [Abstract][Full Text] [Related]
34. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
[TBL] [Abstract][Full Text] [Related]
35. Thrombocytopenia associated with c7E3 Fab (abciximab).
Schell DA; Ganti AK; Levitt R; Potti A
Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
[TBL] [Abstract][Full Text] [Related]
36. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.
Topol EJ; Mark DB; Lincoff AM; Cohen E; Burton J; Kleiman N; Talley D; Sapp S; Booth J; Cabot CF; Anderson KM; Califf RM
Lancet; 1999 Dec; 354(9195):2019-24. PubMed ID: 10636365
[TBL] [Abstract][Full Text] [Related]
37. The use of abciximab in coronary angioplasty--an Asian centre's experience.
Tan HC; Lim YT; Lim TT; Cheng A; Chia BL
Singapore Med J; 2000 Feb; 41(2):69-73. PubMed ID: 11063206
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
[TBL] [Abstract][Full Text] [Related]
39. Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention.
Razakjr OA; Tan HC; Yip WL; Lim YT
J Interv Cardiol; 2005 Feb; 18(1):33-7. PubMed ID: 15788052
[TBL] [Abstract][Full Text] [Related]
40. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
Kandzari DE; Hasselblad V; Tcheng JE; Stone GW; Califf RM; Kastrati A; Neumann FJ; Brener SJ; Montalescot G; Kong DF; Harrington RA
Am Heart J; 2004 Mar; 147(3):457-62. PubMed ID: 14999194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
